Cargando…
Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and co...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406066/ https://www.ncbi.nlm.nih.gov/pubmed/36009471 http://dx.doi.org/10.3390/biomedicines10081924 |
_version_ | 1784774032641490944 |
---|---|
author | Petrillo, Tabatha Semprini, Elisa Tomatis, Veronica Arnesano, Melania Ambrosetti, Fedora Battipaglia, Christian Sponzilli, Alessandra Ricciardiello, Francesco Genazzani, Andrea R. Genazzani, Alessandro D. |
author_facet | Petrillo, Tabatha Semprini, Elisa Tomatis, Veronica Arnesano, Melania Ambrosetti, Fedora Battipaglia, Christian Sponzilli, Alessandra Ricciardiello, Francesco Genazzani, Andrea R. Genazzani, Alessandro D. |
author_sort | Petrillo, Tabatha |
collection | PubMed |
description | Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient’s BMI, the presence or absence of familiar predisposition to diabetes, and the patient’s desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances. |
format | Online Article Text |
id | pubmed-9406066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94060662022-08-26 Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients Petrillo, Tabatha Semprini, Elisa Tomatis, Veronica Arnesano, Melania Ambrosetti, Fedora Battipaglia, Christian Sponzilli, Alessandra Ricciardiello, Francesco Genazzani, Andrea R. Genazzani, Alessandro D. Biomedicines Review Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient’s BMI, the presence or absence of familiar predisposition to diabetes, and the patient’s desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances. MDPI 2022-08-09 /pmc/articles/PMC9406066/ /pubmed/36009471 http://dx.doi.org/10.3390/biomedicines10081924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Petrillo, Tabatha Semprini, Elisa Tomatis, Veronica Arnesano, Melania Ambrosetti, Fedora Battipaglia, Christian Sponzilli, Alessandra Ricciardiello, Francesco Genazzani, Andrea R. Genazzani, Alessandro D. Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients |
title | Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients |
title_full | Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients |
title_fullStr | Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients |
title_full_unstemmed | Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients |
title_short | Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients |
title_sort | putative complementary compounds to counteract insulin-resistance in pcos patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406066/ https://www.ncbi.nlm.nih.gov/pubmed/36009471 http://dx.doi.org/10.3390/biomedicines10081924 |
work_keys_str_mv | AT petrillotabatha putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT semprinielisa putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT tomatisveronica putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT arnesanomelania putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT ambrosettifedora putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT battipagliachristian putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT sponzillialessandra putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT ricciardiellofrancesco putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT genazzaniandrear putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients AT genazzanialessandrod putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients |